Investors don't buy Lyell's solid tumour Car-T success
The ROR1 data are sketchy, and lung toxicity clouds prospects.
Lilly takes two shots at the Nectin goal
A second Lilly Nectin-4 ADC features among the latest phase 1 initiations.
Merck KGaA’s xevinapant gets SMACked down
One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.
The predictable failure of trilaciclib
The CDK4/6 inhibitor flunks its phase 3 study – a result that should have been foreseen five years ago.
Bristol overtakes Amgen in colorectal
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
ALX looks to surprise again
But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.
Toxicity hits BioNTech’s MediLink tie-up
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?
Merck seeks the next Keytruda
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.
Tempest’s pivotal amezalpat conundrum
How does the micro-cap biotech now finance a 700-patient phase 3 study?
Can Wee1 be both alive and dead? Schrödinger hopes so
The company’s SGR-3515 features among the latest industry projects newly into first-in-human trials.
